What Cellid does

Cellid Co., Ltd. (주식회사 셀리드) is a Seoul-headquartered, KOSDAQ-listed (ticker 299660) clinical-stage biopharmaceutical company founded in 2006 from a laboratory at Seoul National University's College of Pharmacy. Its core technology is the CeliVax platform, which uses patient-derived B cells, NK cells, and monocytes as antigen-presenting cells (APCs) — described as a world-first approach — combined with tumor antigen genes and an alpha-galactosyl ceramide immunological adjuvant to simultaneously activate CD8+ T cells, CD4+ T cells, NK cells, NKT cells, and antibody-producing B cells. The platform can be reconfigured by swapping tumor antigens, enabling a pipeline of six BVAC candidates: BVAC-C (HPV-positive cervical cancer, Phase 2 with combination data at ASCO/SGO), BVAC-E6E7 (head and neck cancer, Phase 1/2a initiated December 2025), BVAC-B (HER2+ gastric cancer, Phase 1 complete), BVAC-P (prostate cancer/glioblastoma), BVAC-M (melanoma), and BVAC-Neo (personalized neoantigen therapy licensed to LG Chemistry in May 2021 for up to KRW 1.835 trillion in upfront, milestones, and royalties).

Cellid also operates a proprietary non-replicating adenovirus vector platform, which underpins the AdCLD-CoV19 series of COVID-19 vaccines (AdCLD-CoV19-1, OMI, LP.8.1, BA.3.2). The AdCLD-CoV19-1 OMI Phase 3 trial reported in June 2026 demonstrated a favorable safety profile (26.66% adverse events vs. 66.52% for the Pfizer comparator) but failed to establish immunogenicity non-inferiority versus Pfizer, blocking near-term NDA. Revenue today is dominated by the Gomeon premium baking ingredients e-commerce brand (KRW 85 billion+ in 2025, ~2x growth), with biopharma revenue still primarily milestone-based (e.g., LG Chemistry licensing, government R&D grants from KDDF and Ministry of Science & ICT). The company also runs a CDMO business at its Seongnam GMP facilities (Vector GMP plant 618m², Cell & Gene Therapy GMP plant 925m²) serving domestic and international biotech clients, and has partnerships with IVI, CEPI/COVAX, Vinnex, Samsung Medical Center, and others.

Name

Cellid

Legal name

주식회사 셀리드

Website

https://cellid.co.kr

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Cellid is a KOSDAQ-listed Seoul biopharmaceutical company developing CeliVax-based cancer immunotherapy vaccines (six BVAC candidates) and AdCLD-CoV19 COVID-19 vaccines, using proprietary non-replicating adenovirus vectors, with a CDMO business and a Gomeon e-commerce revenue stream.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

akta.pro secondary industries

Dendritic Cell & Other APC-based Therapies (HLAAABAF), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

Keywords

• Cancer immunotherapy vaccines
• Cell gene therapy CDMO
• Adenovirus vector vaccines
• GMP biopharmaceutical manufacturing
• Infectious disease prevention

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Biopharmaceutical Licensing & Royalties: License-out of CeliVax platform and BVAC pipeline to large pharmaceutical companies for global development and commercialization. Revenue from upfront payments, milestone payments tied to development and regulatory achievements, and ongoing royalties on net sales. Example: LG Chemistry BVAC-Neo license deal valued at up to KRW 1,835 billion including upfront and milestones.
2. CDMO / CMO Services: Cellid operates GMP-certified manufacturing facilities offering contract development and manufacturing services for cell & gene therapies, viral vectors, and vaccines to domestic and international biotech/pharma companies.
3. COVID-19 Vaccine Product Sales: Revenue from sales of COVID-19 preventive vaccines (AdCLD-CoV19 series) to government agencies, hospitals, and international organizations pending regulatory approval. Target markets include national immunization programs and COVAX supply.
4. E-commerce (Gomeon brand): Revenue from premium baking ingredient e-commerce brand 'Gomeon' sold through Naver Smart Store, Coupang and other major online platforms. Reported KRW 85 billion+ revenue in 2025 (2x prior year), providing financial stability separate from biopharma operations.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

Cellid develops anti-cancer immunotherapy vaccines built on its proprietary CeliVax platform, which uses patient-derived B cells, NK cells, and monocytes as antigen-presenting cells combined with tumor antigen genes and alpha-galactosyl ceramide adjuvant to activate multiple anti-tumor immune pathways. The portfolio includes the BVAC pipeline (BVAC-C, BVAC-E6E7, BVAC-B, BVAC-P, BVAC-M, BVAC-Neo) targeting cervical, head and neck, gastric, prostate, melanoma, and personalized cancers, plus the AdCLD-CoV19 series of COVID-19 preventive vaccines. Cellid also operates GMP-certified manufacturing facilities offering CDMO services for cell therapy, gene therapy, and viral vector production to domestic and international biotech and pharmaceutical clients.

Product overview

Cellid is a Korean biotech company developing a portfolio of cancer immunotherapy vaccines and infectious disease preventive vaccines based on its proprietary CeliVax platform technology. The CeliVax platform uses patient-derived B cells, NK cells, and monocytes as antigen-presenting cells to activate comprehensive immune responses against cancer cells. The product portfolio includes six BVAC pipeline products (BVAC-C for cervical cancer, BVAC-E6E7 for head and neck cancer, BVAC-B for gastric cancer, BVAC-P for prostate cancer, BVAC-M for melanoma, and BVAC-Neo for personalized therapy) and multiple COVID-19 vaccine candidates (AdCLD-CoV19-1, AdCLD-CoV19-1 OMI, AdCLD-CoV19-1 LP.8.1). The company also operates CDMO services through its GMP-certified manufacturing facilities for cell therapy, gene therapy, and vaccine production.

Differentiator

Problem solved

Functional benefit

Brands

• CeliVax: Original technology platform for anti-cancer immunotherapeutic vaccines using B cells, NK cells and monocytes
• BVAC-C
• BVAC-E6E7
• BVAC-B
• BVAC-P
• BVAC-M
• BVAC-Neo
• AdCLD-CoV19-1 OMI
• 고메온

Products and services

• CeliVax Platform Cellid's proprietary anti-cancer immunotherapeutic vaccine technology that uses patient-derived B cells, NK cells, and monocytes as antigen-presenting cells combined with tumor antigen genes and an alpha-galactosyl ceramide immunological adjuvant, enabling simultaneous activation of CD8+ T cells, CD4+ T cells, NK cells, NKT cells, and antibody-producing B cells. Applicable to any cancer with identified tumor antigens.
• BVAC-C Anti-cancer immunotherapy vaccine targeting HPV type 16/18 positive cervical cancer using HPV E6/E7 recombinant gene as antigen on the CeliVax platform. In Phase 2 clinical development, with investigator-initiated combination therapy trials with Durvalumab ongoing.
• BVAC-E6E7 Anti-cancer immunotherapy vaccine for head and neck cancer using HPV type 16/18 E6/E7 recombinant gene antigen on the CeliVax platform. Currently in Phase 1/2a clinical trial.
• BVAC-B Anti-cancer immunotherapy vaccine for HER2/neu positive gastric cancer using HER2/neu recombinant gene on the CeliVax platform. Completed Phase 1 clinical trial and preparing for Phase 2.
• BVAC-P Anti-cancer immunotherapy vaccine using PAP/PSMA fusion cancer antigen on the CeliVax platform for prostate cancer, renal cell cancer, and glioblastoma.
• BVAC-M Anti-cancer immunotherapy vaccine using GP100/MAGE-A3 fusion antigen on the CeliVax platform for melanoma.
• BVAC-Neo Fully personalized cancer immunotherapy vaccine using neo-epitopes identified in each individual patient as antigens on the CeliVax platform. Licensed to LG Chemistry for global development and commercialization.
• AdCLD-CoV19-1 COVID-19 preventive vaccine using SARS-CoV-2 spike protein recombinant gene delivered via Cellid's proprietary non-replicating adenovirus vector platform. Completed Phase 2b clinical trial.
• AdCLD-CoV19-1 OMI COVID-19 Omicron variant preventive vaccine using SARS-CoV-2 B.1.1.529 spike protein recombinant gene delivered via Cellid's non-replicating adenovirus vector platform. Phase 3 clinical trial completed with safety endpoint met.
• CDMO Services Contract development and manufacturing organization services offering cell therapy, gene therapy, viral vector (adenovirus, lentivirus, AAV, retrovirus), vaccine, and CAR-T development and GMP manufacturing from early development through commercial supply. Serves domestic and international biotech and pharmaceutical companies.
• GMP Manufacturing Center Global-standard GMP-certified manufacturing facilities including Vector GMP plant, Cell & Gene Therapy GMP plant, BSL2 viral vector production facility, aseptic process room, vial filling lines (1500 vials/hour), LN2 storage, and integrated QC laboratory. Operates under MFDS, ATMP, and human-derived material manufacturing licenses.

Quantifiable outcome

• BVAC-C Phase 2a: ORR 27%, DCR 40% in 15 evaluable patients with recurrent/metastatic cervical cancer; one complete remission maintained >2 years without relapse; PFS 4 months (2-27+ months) and DoR 9-27+ months
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Ten partnerships are on record, tiered major, core and minor.

• Korea National Institute of Health (국립보건연구원)majorStrategic or Co-development Partner · 21 March 2022Clinical trial sample analysis agreement with National Institute of Infectious Diseases under KDCA. NIн provides BSL-3 facilities, national standard reference materials, and standardized testing methods for neutralizing antibody efficacy evaluation of AdCLD-CoV19-1. Analysis enhances international credibility for MFDS approval and WHO PQ certification.
• CEPI / COVAXmajorStrategic or Co-development Partner · 4 October 2021COVAX Marketplace User Agreement signed October 2021. Cellid participates in the CEPI-coordinated international vaccine procurement project for fair and equitable global distribution of COVID-19 vaccines. Cellid requests and offers critical manufacturing supplies and aims to supply AdCLD-CoV19-1 through COVAX pending positive clinical results and WHO EUL approval.
• Vinnex (바이넥스)majorChannel Partner/ Reseller/ Distributor · 30 August 2021CMO (contract manufacturing organization) agreement for large-scale commercial production of COVID-19 vaccine AdCLD-CoV19-1. Vinnex leverages its 12,000L bioreactor capacity to provide additional manufacturing capability for vaccine supply. Partnership supports domestic and WHO emergency approval production needs.
• International Vaccine Institute (IVI, 국제백신연구소)coreStrategic or Co-development Partner · 29 June 2021Clinical development cooperation agreement for global Phase 2b/3 trials and regulatory approval of AdCLD-CoV19-1 COVID-19 vaccine. IVI provides international clinical trial expertise, regulatory strategy support, and connections to WHO and global health agencies. Trial results intended for submission to Korean MFDS, WHO, and multiple international regulatory authorities.
• LG Chemistry (LG화학)coreOEM/ Whitelabel/ Licensing Partner · 26 May 2021Global license-out agreement for CeliVax-based personalized neoantigen cancer immunotherapy vaccine (BVAC-Neo). Cellid receives KRW 10 billion upfront payment, up to KRW 1,825 billion in development and regulatory milestones, plus royalties on net sales. LG Chemistry gains exclusive worldwide rights for development and commercialization of personalized cancer vaccines using Cellid's CeliVax platform technology combined with LG's own cell therapy platform.
• International Vaccine Institute (IVI, 국제백신연구소)coreStrategic or Co-development Partner · 4 January 2021Research service contract for safety and immunogenicity analysis of COVID-19 vaccine AdCLD-CoV19 clinical trial specimens. IVI analyzes clinical samples from Phase 1/2a trials to evaluate safety and immunogenicity profiles.
• Korea University Guro Hospital (고려대학교 구로병원)majorStrategic or Co-development Partner · 18 December 2020Clinical trial service agreement for Phase 1/2a of COVID-19 vaccine AdCLD-CoV19 at Guro Hospital, led by Professor Hee-Jin Jeong. Hospital serves as primary clinical trial site for early-stage COVID-19 vaccine development. Additional sites: Korea University Ansan Hospital, Hallym University Kangnam Sacred Heart Hospital, Catholic University Seoul St. Mary's Hospital, and Catholic University St. Vincent's Hospital.
• Animal Cell Technology Center (동물세포실증지원센터)majorStrategic or Co-development Partner · 13 July 2020COVID-19 vaccine production cooperation agreement. Center provides GMP manufacturing facility and expertise for clinical trial vaccine production. Located in Andong Bioindustry Complex with BSL-level facilities and 16,120m² GMP manufacturing building. Partnership is part of a three-site production network (Seongnam GMP + Jeonnam JBRC + Andong Animal Cell Center).
• Samsung Medical Center (삼성서울병원)majorStrategic or Co-development PartnerInvestigator-initiated clinical trial of BVAC-C in combination with Durvalumab for recurrent cervical cancer, led by Professor Byung-Kee Kim. Trial approved August 2020 (25 patients). Phase 2 results presented at SGO 2025 and ASCO 2024. Samsung Medical Center serves as lead site for BVAC-C + checkpoint inhibitor combination studies.
• Handok Co., Ltd. (한독)minorOthersCEO Kang Chang Yuil serves as Non-Executive Director at Handok Co., Ltd., a listed Korean pharmaceutical company, providing potential strategic connection to pharmaceutical distribution and commercialization networks.

Scale indicators8 records

Recent moves11 records

Expansion highlights6 records

Broad incumbents

• BioNTech: mRNA-based cancer vaccine pipeline (BNT122/iNeST, BNT111, etc.) and infectious disease vaccines. Comparable to Cellid as a leading therapeutic cancer vaccine developer with multiple oncology programs targeting similar indications (HPV-driven cancers, melanoma, personalized neoantigens).
• Novavax: Recombinant nanoparticle vaccine developer for infectious diseases (COVID-19, influenza, RSV) with Matrix-M adjuvant platform. Comparable to Cellid on the infectious disease vaccine side (AdCLD-CoV19 series) where both pursued COVID-19 vaccines and faced mRNA-driven competitive pressure.
• Moderna: mRNA platform with extensive oncology vaccine pipeline (mRNA-4157/V940 individualized neoantigen therapy, mRNA-5671 KRAS, Merck partnership) plus infectious disease vaccines. Highly comparable therapeutic cancer vaccine approach to CeliVax and BVAC-Neo via individual neoantigen targeting.

Regional players

• Celltrion: Korean biopharma leader with biosimilars, novel biologics, and CDMO services through Celltrion Pharm. Comparable to Cellid as a Korean biopharma with significant GMP manufacturing scale and CDMO operations, illustrating the scale gap and providing a benchmark for Korean biopharma CDMO economics.
• Genexine: Korean KOSDAQ-listed biotech developing immunotherapies and DNA vaccines, including therapeutic cancer vaccine candidates (GX-188E for HPV-driven cervical cancer). Comparable to Cellid as a fellow Korean biotech operating in therapeutic cancer vaccines and HPV-driven indications, though with a DNA vaccine rather than APC approach.

Direct peers

• CureVac: mRNA-based cancer vaccine developer (CV8102, CV9202, personalized neoantigen vaccines) and infectious disease vaccines. Comparable to Cellid as a smaller-cap cancer/infectious disease vaccine biotech with platform-anchored multiple indication expansion strategy.
• Gritstone bio: Clinical-stage biotech developing personalized neoantigen cancer vaccines (similar to Cellid's BVAC-Neo). Both companies pursue individualized cancer immunotherapy using patient-specific tumor antigens, making Gritstone the most directly comparable peer on the personalized vaccine side of CeliVax.
• VBI Vaccines: Vaccine biotech developing prophylactic and therapeutic vaccines including enveloped virus-like particle (eVLP) platforms for infectious disease and immunotherapeutic candidates. Comparable to Cellid as a small-cap multi-platform vaccine company pursuing both infectious disease and oncology indications.
• Bavarian Nordic: Vaccine-focused biotech with both infectious disease (smallpox/mpox, COVID-19, RSV) and oncology immunotherapy vaccine programs. Comparable to Cellid for its dual focus on prophylactic vaccines plus therapeutic cancer vaccines (CV301, BN-CV301) and global commercial reach.

Emerging players

• JW Therapeutics: Asia-Pacific cell therapy company developing CAR-T therapies (Carteyva/relmacabtagene autoleucel) with integrated GMP manufacturing. Comparable to Cellid on the cell/gene therapy manufacturing side given Cellid's GMP facility and CDMO ambitions for cell therapy and viral vector production.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellid